文献速递胸部肿瘤放疗姑息放疗与转移瘤

肺癌EGFR突变与放疗反应:多中心临床研究

Lung cancer epidermal growth factor receptor mutations and radiotherapy response: A multicentre clinical study.
PubMed 文献 · Clin Transl Radiat Oncol · 2021-07-01

该多中心回顾性研究纳入121例转移性非小细胞肺癌(NSCLC)患者,评估EGFR突变状态对姑息性胸部放疗客观缓解的影响。结果显示EGFR突变状态并非独立预测因素,放疗后启动酪氨酸激酶抑制剂(TKI)与更高缓解率相关,而TKI耐药后疾病进展者放疗缓解率更差。

要点

  • EGFR突变状态与姑息性胸部放疗客观缓解率无显著差异(49% vs 63%,p=0.21)。
  • 放疗后启动TKI与更高缓解率独立相关(OR=5.07,95%CI 1.08-23.69,p=0.039)。
  • EGFR+患者中,TKI耐药后进展者放疗缓解率低于TKI初治者(30% vs 77%,p=0.018)。

核心结论

  • EGFR突变状态本身不是转移性NSCLC患者对姑息性胸部放疗客观影像学缓解的独立预测因素。
  • 获得性TKI耐药可能与疾病对姑息性放疗的交叉耐药相关。

研究设计与样本

  • 多中心回顾性研究,纳入2010年3月至2012年6月诊断为转移性NSCLC并接受胸部姑息性放疗的患者。
  • 纳入标准为具有放疗前基线影像及放疗后1-3个月随访影像,共121例患者。
  • 按EGFR突变状态分为EGFR阳性(EGFR+)和EGFR野生型(WT)队列进行比较分析。

主要发现

  • 121例患者中,EGFR WT 89例(74%),EGFR+ 32例(26%)。
  • EGFR WT与EGFR+队列的缓解率无显著差异(49% vs 63%,p=0.21)。
  • 多因素分析显示,放疗后启动TKI与更高缓解率相关(OR:5.07,95%CI:1.08-23.69,p=0.039),而EGFR突变状态与缓解率无独立关联。
  • EGFR+队列中,初始TKI治疗期间疾病进展者较放疗前未接受TKI者缓解率更差(30% vs 77%,p=0.018)。
  • 两EGFR队列间局部控制无统计学差异。

关键数值与推荐

  • 主要终点为放疗后1-3个月局部客观影像学缓解,采用RECIST标准评估。
  • EGFR+队列中TKI耐药后进展者与TKI初治者的缓解率分别为30%和77%(p=0.018)。

临床怎么用

  • 对于转移性NSCLC患者接受姑息性胸部放疗,不应仅依据EGFR突变状态预测放疗缓解。
  • 放疗后启动TKI可能提高缓解率,需结合临床情况考虑TKI的时序安排。
  • 对TKI耐药后进展的EGFR+患者,应预期其对姑息性放疗的缓解可能较差。

局限性

  • 回顾性多中心研究设计,可能存在选择偏倚和信息偏倚。
  • 样本量有限,EGFR+队列仅32例,亚组分析效能不足。
  • 仅评估1-3个月短期影像学缓解,缺乏长期生存及局部控制数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To examine the impact of epidermal growth factor receptor (EGFR) mutations on objective response to palliative lung radiotherapy in patients with metastatic non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: A multicentre retrospective study was conducted of patients with metastatic NSCLC diagnosed between March 2010 and June 2012 who received palliative radiotherapy to the chest. Patients included for study had baseline imaging and follow-up imaging 1-3 months after radiotherapy. The primary endpoint was 1-3 month local objective imaging response by the Response Evaluation Criteria in Solid Tumours (RECIST). Patients were divided into EGFR mutation positive (EGFR+) and EGFR wild type (WT) cohorts for analysis. RESULTS: There were 121 patients for study inclusion: 89 (74%) were EGFR WT and 32 (26%) were EGFR+. The response rate between EGFR WT and EGFR+ cohorts was not significantly different (49 vs. 63%, p = 0.21). On multivariate analysis, initiation of a tyrosine kinase inhibitor (TKI) after radiotherapy was associated with a higher rate of response (OR: 5.07, 95%CI: 1.08-23.69, p = 0.039) but EGFR mutation status was not. For the EGFR+ cohort, patients with disease progression after initial management on a TKI had a worse response rate compared to patients who were TKI-naïve before starting radiotherapy (30 vs. 77%, p = 0.018). Local control was not statistically different between the EGFR cohorts. CONCLUSION: The EGFR mutation status alone was not an independent predictor of objective radiographic response to palliative thoracic radiotherapy. Acquired resistance to TKI therapy may be associated with disease cross-resistance to palliative radiotherapy.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Hsu F, Sit D, Pastuch A, et al. Lung cancer epidermal growth factor receptor mutations and radiotherapy response: A multicentre clinical study. Clin Transl Radiat Oncol. 2021. PMID: 34278010. doi:10.1016/j.ctro.2021.06.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。